患者对改变其生活的抗癌药物的可及性继续承受成本的快速增长，造成了消极影响。此外，不断上升的成本并不能等同于药物疗效的相似增长。我们认识到作为大学医院的责任，我们要解决这种不平衡，并努力提供高质量、可持续、负担得起和可访问的护理。我们的机构采取了主动的方法，对昂贵和创新的抗癌药物进行成本控制，以保障患者的可及性和改善生活质量。在本文中，我们描述了四种干预方法：1）确定合适的患者并减少过度治疗，2）内部生产特定适应症的药物，3）减少药物浪费，4）有效的采购策略。我们呼吁其他医院采取行动，并愿意在欧洲层面上合作。共同来保障我们患者的当前和未来护理。版权所有 © 2023 Dane, van Leeuwen, Hoedemakers, van der Kuy and Sleijfer.

Rapid increase in cost continues to have negative impact on patients' accessibility to life-changing anticancer medications. Moreover, the rising cost does not equate to similar increase in medication effectiveness. We recognise our responsibility as a university hospital to tackle this imbalance and strive to provide high quality, sustainable, affordable and accessible care. An active approach in cost containment of expensive and innovative cancer drugs was adopted in our organisation to safeguard accessibility and improve quality of life for patients. In this article, we described four inverventions: 1) identify right patient and minimise overtreatment, 2) in-house medicine production for selected indications, 3) minimise medicine spillages and 4) effective procurement strategies. We call on other hospitals to take action and, favourably, to collaborate on a European level. Together, we will safeguard the current and future care of our patients.Copyright © 2023 Dane, van Leeuwen, Hoedemakers, van der Kuy and Sleijfer.